Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jacobs, 1992, Report of the conference on low blood cholesterol: mortality associations, Circulation, 86, 1046, 10.1161/01.CIR.86.3.1046
Stamler, 1993, Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434
Chen, 1990
Chen, 1991, Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations, BMJ, 303, 276, 10.1136/bmj.303.6797.276
Szatrowski, 1984, Serum cholesterol levels, other risk factors, and cardiovascular disease in a Japanese cohort, J Chron Dis, 7, 569, 10.1016/0021-9681(84)90007-9
1995, Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts, Lancet, 346, 1647, 10.1016/S0140-6736(95)92836-7
1998, Blood pressure, cholesterol, and stroke in eastern Asia, Lancet, 352, 1801, 10.1016/S0140-6736(98)03454-0
2003, Cholesterol, coronary heart disease, and stroke in the Asia Pacific region, Int J Epidemiol, 32, 563, 10.1093/ije/dyg106
Iso, 1989, Serum cholesterol levels and six-year mortality from stroke in 350977 men screened for the multiple risk factor intervention trial, N Engl J Med, 320, 904, 10.1056/NEJM198904063201405
Iribarren, 1995, Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men, JAMA, 273, 1926, 10.1001/jama.1995.03520480046038
Law, 2003, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis, BMJ, 326, 1423, 10.1136/bmj.326.7404.1423
Hebert, 1995, An overview of trials of cholesterol lowering and risk of stroke, Arch Intern Med, 155, 50, 10.1001/archinte.1995.00430010054007
White, 2000, Pravastatin therapy and the risk of stroke, N Engl J Med, 343, 317, 10.1056/NEJM200008033430502
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
Plehn, 1999, Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study, Circulation, 99, 216, 10.1161/01.CIR.99.2.216
The Post Coronary Artery Bypass Graft Trial Investigators, 1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615
Hebert, 1997, Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials, JAMA, 278, 313, 10.1001/jama.1997.03550040069040
Di Mascio, 2000, Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials, Cerebrovasc Dis, 10, 85, 10.1159/000016035
Furberg, 1994, Effects of lovastatin on early carotid atherosclerosis and cardiovascular events, Circulation, 90, 1679, 10.1161/01.CIR.90.4.1679
Crouse, 1995, Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II), Am J Cardiol, 75, 455, 10.1016/S0002-9149(99)80580-3
MacMahon, 1998, Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy, Circulation, 97, 1784, 10.1161/01.CIR.97.18.1784
Amarenco, 2001, Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction, Neurology, 57, S35, 10.1212/WNL.57.suppl_2.S35
1999, MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience, Eur Heart J, 20, 725, 10.1053/euhj.1998.1350
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7
Thorvaldsen, 1995, Stroke incidence, case fatality, and mortality in the WHO MONICA Project, Stroke, 26, 361, 10.1161/01.STR.26.3.361
Bamford, 1989, Interobserver agreement for the assessment of handicap in stroke patients, Stroke, 20, 828, 10.1161/01.STR.20.6.828
Peto, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient, Br J Cancer, 35, 1, 10.1038/bjc.1977.1
Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712
Rockwood, 2002, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people, Arch Neurol, 59, 223, 10.1001/archneur.59.2.223
Wagstaff, 2003, Statin-associated memory loss: analysis of 60 case reports and review of the literature, Pharmacotherapy, 23, 871, 10.1592/phco.23.7.871.32720
Collins, 2001, Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials, Lancet, 357, 373, 10.1016/S0140-6736(00)03651-5
De Jager, 2003, Utility of TICS-M for the assessment of cognitive function in older adults, Int J Geriatr Psychiatry, 18, 318, 10.1002/gps.830
Gaist, 2001, Areusers of lipid-lowering drugs at increased risk of peripheral neuropathy?, Eur J Clin Pharmacol, 56, 931, 10.1007/s002280000248
Gaist, 2002, Statins and risk of neuropathy: a case-control study, Neurology, 58, 1333, 10.1212/WNL.58.9.1333
Wolf, 1999, Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association, Stroke, 30, 1991, 10.1161/01.STR.30.9.1991
Goldstein, 2001, Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association, Circulation, 103, 163, 10.1161/01.CIR.103.1.163
2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?, Ital Heart J, 1, 810
Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X
Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, Curr Med Res Opin, 4, 220, 10.1185/030079902125000787
2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT), JAMA, 288, 2998, 10.1001/jama.288.23.2998
Sever, 2003, Prevention of coronary and stroke events with atorvastatin in hypertensive subjects who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid lowering arm (ASCOT–LLA), Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0
Byington, 2001, Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project, Circulation, 103, 387, 10.1161/01.CIR.103.3.387
1995, Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens, Am J Cardiol, 75, 1130, 10.1016/S0002-9149(99)80744-9
2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486
The SPARCL Investigators, 2003, Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study, Cerebrovasc Dis, 16, 389, 10.1159/000072562
Murray, 1996